The Filing Desk

Genelux

GNLX · Nasdaq · Health Care · Financials, fiscal 2022 to 2025

GNLX · Last close · November 19, 2026
$2.28
Value Genelux yourself

Genelux's revenue was flat at $0 million in fiscal 2025. Its operating margin was −415,175.0%, down from −396,200.0% a year earlier. Free cash flow was −$26 million. The diluted share count rose 18.2%.

GENELUX CORPORATION Latest fiscal year ended December 31, 2025 10-K filed March 19, 2026 · 0001493152-26-011616 Updated
Revenue
$0M
flat
Operating margin
−415,175.0%
18975.0 pts
Net income
−$32M
 
Free cash flow
−$26M
 
Return on equity
−170.0%
39.4 pts
Market cap
$103M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Genelux does

Genelux is a drug developer in Westlake Village, California, working on cancer treatments made from viruses. Its drug candidates are modified strains of the vaccinia virus, meant to infect and kill tumor cells and prompt the patient's immune system to attack the tumor. It has no approved products and has never had revenue from product sales.

Its lead candidate, Olvi-Vec, is in three trials: a final-stage (Phase 3) U.S. trial in ovarian cancer that no longer responds to platinum chemotherapy, a Phase 2 U.S. trial in a common type of lung cancer (non-small cell), and an early-to-mid-stage trial in China in small cell lung cancer. A key aim is to show that Olvi-Vec can make tumors respond to platinum chemotherapy again. Genelux has licensed the rights to Olvi-Vec in mainland China, Taiwan, Hong Kong and Macau to a partner, Newsoara, and plans to keep U.S. rights and build its own sales team there. It also has a library of hundreds of other virus versions for future candidates.

Genelux makes its own trial supplies at a plant in San Diego. It lost $32.1 million in 2025.

Its biggest risks, as it describes them

  • Continued losses and the need to raise more money; its auditor has raised substantial doubt about its ability to keep going.
  • Its future rests largely on Olvi-Vec, its only drug candidate in clinical trials, which may fail or not be approved.
  • Delays or setbacks in its trials, including the Phase 3 ovarian cancer trial.
  • Competition from many other cancer treatments, including other virus-based therapies and antibody drugs.
  • Problems making its products at its own plant, or building a business to sell them if approved.
From Genelux's annual report on Form 10-K, filed March 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Genelux lost money in fiscal 2025: a net loss of $32 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25
Cash and short-term investments02331—
Debt incl. finance leases8———
Net debt (negative means net cash)8———
Net debt to EBITDA————
Debt to equity————
Interest coverage−11.4x−139.7x——
Current ratio0.1x3.7x4.6x2.4x
Quick ratio0.1x3.7x4.6x2.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Genelux's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Genelux shares on the open market, and 6 insiders sold $327,695, $108,800 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 31, 2026Thomas ZindrickPresident and CEOSold34,463$2.67$92,016Form 4
Aug 31, 2026Joseph CappelloChief Technical OfficerSold10,257$2.74$28,104Form 4
Aug 31, 2026Yong YuChief Scientific OfficerSold9,683$2.75$26,628Form 4
Aug 4, 2026Thomas ZindrickPresident and CEOSold3,023$2.95$8,918Form 4
Aug 4, 2026Joseph CappelloChief Technical OfficerSold653$2.95$1,926Form 4
Aug 4, 2026Yong YuChief Scientific OfficerSold653$2.94$1,920Form 4
Jul 1, 2026John W SmitherDirectorSold12,000$2.91$34,920Form 4
Jun 3, 2026Ralph SmallingHead of RegulatorySold192$2.93$563Form 4
Jun 1, 2026John ThomasDirectorSold plan10,000$2.98$29,800Form 4
May 11, 2026Thomas ZindrickPresident and CEOSold2,798$2.94$8,226Form 4
May 11, 2026Yong YuChief Scientific OfficerSold605$2.97$1,797Form 4
May 11, 2026Ralph SmallingHead of RegulatorySold270$2.98$805Form 4
The latest 12 of 19 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−12,627.9%−270,207.8%−329,575.0%
Altman Z''−25.13−21.82−55.62
Accruals ratio−48.0%−27.6%−25.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rose—PassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets—FailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Genelux side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
GeneluxFY250.0%−415,175.0%−329,575.0%———
Aardvark TherapeuticsFY25——————Compare
ABVC BioPharmaFY25−41.9%−2,416.0%————Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

4 years of figures

Fiscal yearFY22FY23FY24FY25
Income statement
Revenue11000
Revenue growth—−98.5%−95.3%0.0%
Gross profit————
Research and development9131920
Operating income−3−24−32−33
Net income−5−28−30−32
Diluted EPS (US$)−0.57−1.16−0.95−0.86
Diluted shares (millions)9243237
Cash flow
Cash from operations−4−20−21−25
Capital expenditure0101
Free cash flow−4−21−22−26
Dividends paid0000
Share buybacks0000
Acquisitions0000
Stock-based compensation2266
Balance sheet at fiscal year end
Cash and short-term investments02331—
Debt incl. finance leases8———
Total assets6283519
Total liabilities41888
Shareholders' equity−36202612
Margins and ratios
Gross margin————
Operating margin−27.2%−14,214.7%−396,200.0%−415,175.0%
Net margin−47.0%−16,645.3%−373,362.5%−401,812.5%
Free cash flow margin−32.7%−12,529.4%−270,112.5%−329,575.0%
Rule of 40 (growth + FCF margin)—−12,627.9%−270,207.8%−329,575.0%
Return on capital————
Return on equity——−130.6%−170.0%
Return on assets—−169.3%−95.4%−119.6%
Net debt to EBITDA————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Genelux's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Genelux.